返回
Disease biomarker identification based on sample network optimization
DOI:10.1016/j.ymeth.2023.03.005.png)
摘要
En 中文
A large amount of evidence shows that biomarkers are discriminant features related to disease development. Thus, the identification of disease biomarkers has become a basic problem in the analysis of complex diseases in the medical fields, such as disease stage judgment, disease diagnosis and treatment. Research based on networks have become one of the most popular methods. Several algorithms based on networks have been proposed to identify biomarkers, however the networks of genes or molecules ignored the similarities and associations among the samples. It is essential to further understand how to construct and optimize the networks to make the identified biomarkers more accurate. On this basis, more effective strategies can be developed to improve the performance of biomarkers identification. In this study, a multi-objective evolution algorithm based on sample similarity networks has been proposed for disease biomarker identification. Specifically, we design the sample similarity networks to extract the structural characteristic information among samples, which used to calculate the influence of the sample to each class. Besides, based on the networks and the group of biomarkers we choose in every iteration, we can divide samples into different classes by the importance for each class. Then, in the process of evolution algorithm population iteration, we develop the elite guidance strategy and fusion selection strategy to select the biomarkers which make the sample classification more accurate. The experiment results on the five gene expression datasets suggests that the algorithm we proposed is superior over some state-of-the-art disease biomarker identification methods.
Keyword:
Disease biomarker identification
Sample similarity network
Multi-objective evolution algorithm
Sample classification
期刊
IF:
4.3
论文数:
4.8K
被引数:
2.4W
机构
引用论文
Targeted Exome Sequencing of Krebs Cycle Genes Reveals Candidate Cancer-Predisposing Mutations in Pheochromocytomas and Paragangliomas
CLINICAL CANCER RESEARCH
IF10.2
A statistical framework for assessing pharmacological responses and biomarkers using uncertainty estimates
ELIFE
IF0
A highly efficient protein corona-based proteomic analysis strategy for the discovery of pharmacodynamic biomarkers基于蛋白质冠的高效蛋白质组学分析策略,用于发现药效学生物标志物

